Oncology Today with Dr Neil Love

Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon

Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo

Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress

HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Metastatic Bladder Cancer — Rapid Case Review Issue 8

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Non-Small Cell Lung Cancer — Targeting KRAS G12C

Targeting KRAS G12C mutations in non-small cell lung cancer represents a rapidly evolving frontier in oncology, necessitating a shift toward clinical trial participation as the primary treatment strategy. While first-generation inhibitors like sotorasib and adagrasib established proof-of-concept, next-generation agents...

Prostate Cancer — The Optimal Use of Hormonal Therapy